For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7 percent ...

A growing body of research says the Body Mass Index (BMI) method is outdated. Here’s why waist-to-height ratio is gaining ...

Louisiana is facing a significant obesity challenge, ranking fourth in the nation for obesity rates. As a result, many residents are turning to weight loss drugs like Ozempic and Wegovy.

The Global Liver Institute urges worldwide integration of liver health into diabetes and obesity care as steatotic liver ...

Indian contract drug manufacturer OneSource Specialty Pharma expects strong growth in its order book over the next three years, driven by the global boom in weight-loss drugs, its top executive said ...

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...

Novo Nordisk will pay U.S. biotech Deep Apple Therapeutics up to $812 million in a partnership deal aimed at developing drugs to treat cardiometabolic diseases, including obesity.

People who take weight-loss drugs hoping to achieve the impressive results observed in large clinical trials may need to ...

A new study shows weight-loss drugs, such as Novo Nordisk's Wegovy and Eli Lilly's Mounjaro, yield lower weight reductions in ...

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren’t as impressive as those promised ...

Researchers found that injectable GLP-1 receptor agonists for obesity tended to yield smaller reductions in weight in ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk ...